Clinical Trial Detail

NCT ID NCT02287311
Title Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Baylor College of Medicine
Indications

nasopharynx carcinoma

non-Hodgkin lymphoma

lymphoma

Advanced Solid Tumor

smooth muscle tumor

Hodgkin's lymphoma

Therapies

LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes

Cyclophosphamide + Fludarabine

Age Groups: adult child senior

No variant requirements are available.